Ring Therapeutics Turns To Anelloviruses To Disrupt Gene Therapy Space
Ring Therapeutics is turning to a previously unexplored family of viruses to improve the safety and efficacy of gene therapy. The preclinical science suggests using these anelloviruses as vectors can deliver payloads precisely and without causing a significant immune response. Human trials will need to demonstrate the technology can live up to its disruptive potential.
You may also be interested in...
Robotic-assisted surgery is moving into a different phase of growth. New competitors with new ideas are coming into the industry and user awareness has been enhanced. UK scale-up CMR Surgical views these as healthy developments, says business development chief Bertrand Weil.
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.